Hypomethylating agents for urologic cancers.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Future Oncology

• Publication date

  2011-03-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fon.11.9PMID 21417907
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.

  2011cited by this paper
• 5‐azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors

  2010cited by this paper
• Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer

  2010cited by this paper
• Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples

  2010cited by this paper
• Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells

  2010cited by this paper
• A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

  2010cited by this paper
• Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

  2010cited by this paper
• The functional significance of microRNA-145 in prostate cancer

  2010cited by this paper
• Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics

  2010cited by this paper
• Epigenetic Modifications as Therapeutic Targets

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Maintenance treatment with azacytidine for patients with high‐risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

  2010cited by this paper
• Cabazitaxel

  2010cited by this paper
• Global Methylation Pattern of Genes in Androgen-Sensitive and Androgen-Independent Prostate Cancer Cells

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Implications of LINE1 Methylation for Bladder Cancer Risk in Women

  2010cited by this paper
• Identification of Methylated Genes Associated with Aggressive Bladder Cancer

  2010cited by this paper
• Role of DNA methyltransferase 1 in hormone-resistant prostate cancer

  2010cited by this paper
• Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma.

  2010cited by this paper
• Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance

  2010cited by this paper
• Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer.

  2009cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors

  2009cited by this paper
• CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma

  2009cited by this paper
• Increased Expression of Androgen Receptor Coregulator MAGE-11 in Prostate Cancer by DNA Hypomethylation and Cyclic AMP

  2009cited by this paper
• Study of 5-Aza-CdR on Transcription Regulation of RASSF1A Gene in the BIU87 Cell Line

  2009cited by this paper
• Experimental Therapeutic s , Molecular Targets , and Chemical Biology High DNA Methyltransferase 3 B Expression Mediates 5-Aza-Deoxycytidine Hypersensitivity in Testicular Germ Cell Tumors

  2009cited by this paper
• Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.

  2009cited by this paper
• Multigene Methylation Analysis of Conventional Renal Cell Carcinoma

  2009cited by this paper
• The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

  2009cited by this paper
• Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target.

  2009cited by this paper
• Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.

  2009cited by this paper
• Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas

  2009cited by this paper
• Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients.

  2009cited by this paper
• Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

  2009cited by this paper
• Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen‐independent prostate cancer cells

  2008cited by this paper
• DNA demethylation and histone deacetylation inhibition co‐operate to re‐express estrogen receptor beta and induce apoptosis in prostate cancer cell‐lines

  2008cited by this paper
• Epigenetics in cancer.

  2008cited by this paper
• Identification of PMF1 Methylation in Association with Bladder Cancer Progression

  2008cited by this paper
• Promoter hypermethylation in circulating blood cells identifies prostate cancer progression

  2008cited by this paper
• Genetic Clustering of Clear Cell Renal Cell Carcinoma Based on Array-Comparative Genomic Hybridization: Its Association with DNA Methylation Alteration and Patient Outcome

  2008cited by this paper
• Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

  2008cited by this paper
• A pilot pharmacokinetic study of oral azacitidine

  2008cited by this paper
• CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer.

  2008cited by this paper
• High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.

  2007cited by this paper
• DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer

  2007cited by this paper
• Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma.

  2007cited by this paper
• Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays

  2007cited by this paper
• 5-Aza-2′-Deoxycytidine Delays Androgen-Independent Disease and Improves Survival in the Transgenic Adenocarcinoma of the Mouse Prostate Mouse Model of Prostate Cancer

  2007cited by this paper
• Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer.

  2007cited by this paper
• Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome

  2007cited by this paper
• DNA methyltransferases as targets for cancer therapy.

  2007cited by this paper
• Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides.

  2007cited by this paper
• Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.

  2007cited by this paper
• The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5‐azacytidine in human bladder cancer therapy

  2007cited by this paper
• Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer

  2007cited by this paper
• Decitabine improves patient outcomes in myelodysplastic syndromes

  2006cited by this paper
• Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool.

  2006cited by this paper
• LUMA (LUminometric Methylation Assay)--a high throughput method to the analysis of genomic DNA methylation.

  2006cited by this paper
• Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.

  2006cited by this paper
• Cytogenetic and expression profiles associated with transformation to androgen‐resistant prostate cancer

  2006cited by this paper
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use

  2006cited by this paper
• A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters

  2006cited by this paper
• Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura

  2006cited by this paper
• Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

  2006cited by this paper
• Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.

  2006cited by this paper
• Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis.

  2006cited by this paper
• UROLOGICAL ONCOLOGY: RENAL, URETERAL AND RETROPERITONEAL TUMORS Molecular Profiling and Classification of Sporadic Renal Cell Carcinoma by Quantitative Methylation Analysis

  2006cited by this paper
• Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer

  2006cited by this paper
• Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

  2006cited by this paper
• Epigenetic Inactivation of Wnt Inhibitory Factor-1 Plays an Important Role in Bladder Cancer through Aberrant Canonical Wnt/β-Catenin Signaling Pathway

  2006cited by this paper
• RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.

  2005cited by this paper
• Ras-mediated Loss of the Pro-apoptotic Response Protein Par-4 Is Mediated by DNA Hypermethylation through Raf-independent and Raf-dependent Signaling Cascades in Epithelial Cells*

  2005cited by this paper
• Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells.

  2005cited by this paper
• Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.

  2005cited by this paper
• Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells.

  2005cited by this paper
• Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci

  2005cited by this paper
• Promoter CpG hypermethylation and downregulation of DICE1 expression in prostate cancer

  2005cited by this paper
• Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy

  2005cited by this paper
• Recruitment of DNA methyltransferase I to DNA repair sites.

  2005cited by this paper
• Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

  2005cited by this paper
• Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.

  2005cited by this paper
• Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.

  2005cited by this paper
• Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.

  2005cited by this paper
• Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome?

  2005cited by this paper
• Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation

  2004cited by this paper
• Zebularine: a new drug for epigenetic therapy.

  2004cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• DNA hypo‐methylating agents and sickle cell disease

  2004cited by this paper
• Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer

  2004cited by this paper
• Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells

  2004cited by this paper
• GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer

  2004cited by this paper
• Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line

  2004cited by this paper
• Inactivation of the hMSH3 mismatch repair gene in bladder cancer.

  2004cited by this paper
• Multipoint methylation and expression analysis of tumor suppressor genes in human renal cancer cells.

  2003cited by this paper
• Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma

  2003cited by this paper
• Gene silencing in cancer in association with promoter hypermethylation.

  2003cited by this paper
• Phase I trial of continuous infusion 5-aza-2′-deoxycytidine

  2003cited by this paper

• Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043

  2024cites this paper
• Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes

  2021cites this paper
• DNA methyltransferases in hematologic malignancies.

  2013cites this paper
• 2′-Deoxyriboguanylurea, the primary breakdown product of 5-aza-2′-deoxyribocytidine, is a mutagen, an epimutagen, an inhibitor of DNA methyltransferases and an inducer of 5-azacytidine-type fragile sites

  2012cites this paper
• The role of epigenetic regulation in stem cell and cancer biology

  2012cites this paper
• Epigenetics in Prostate Cancer

  2011influential citation
• The functional significance of microRNA-145 in prostate cancer

  2010cites this paper